Found: 2
Select item for more details and to access through your institution.
Penpulimab, an Fc-Engineered IgG1 Anti-PD-1 Antibody, With Improved Efficacy and Low Incidence of Immune-Related Adverse Events.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.924542
- By:
- Publication type:
- Article
Penpulimab, an anti-PD1 IgG1 antibody in the treatment of advanced or metastatic upper gastrointestinal cancers.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 10, p. 2371, doi. 10.1007/s00262-022-03160-1
- By:
- Publication type:
- Article